Patient Risk Should Not Sway Process Validation Decision-Making - Sulzer
This article was originally published in The Gray Sheet
Executive Summary
Patient risk should not be used as a factor in determining whether a medical device firm's manufacturing process should be validated as the Global Harmonization Task Force Study Group 3's draft "Process Validation Guidance" suggests, Sulzer Medica says in Aug. 13 comments to FDA.